Wednesday, March 18, 2015 8:22:57 AM
Quote:
________________________________________
GEN News HighlightsMore »
Nov 6, 2014
Aeterna Zentaris Ponders Macrilen's Future after FDA Setback
Aeterna Zentaris said today it is assessing the future of its registrational adult growth hormone deficiency (AGHD) treatment MacrilenTM (macimorelin) after receiving a Complete Response Letter from the FDA.
The FDA told Aeterna Zentaris its NDA for Macrilen cannot be approved in its present form. The agency cited concerns about data from the company’s Phase III pivotal trial of the drug candidate, the company added.
"Following the FDA's decision, we are currently reviewing the outstanding issues stated in the CRL in order to evaluate our options and future plans for Macrilen," David Dodd, Aeterna Zentaris’ chairman and CEO, said in a statement.
Macrilen is an orally-active ghrelin agonist designed to stimulate the secretion of growth hormone. The compound has been granted orphan drug designation by the FDA for AGHD.
In its Complete Response Letter, the FDA said the planned analysis of the pivotal trial did not meet its stated primary efficacy objective as agreed to in a Special Protocol Assessment agreement between the company and the agency.
The letter also cited issues related to what it said was the lack of complete and verifiable source data for determining whether patients were accurately diagnosed with AGHD.
"In light of the failed primary analysis and data deficiencies noted, the clinical trial does not by itself support the indication," the FDA stated in its letter, according to Aeterna Zentaris.
To address the deficiencies it identified, the FDA added, Aeterna Zentaris will need to demonstrate the efficacy of macimorelin as a diagnostic test for growth hormone deficiency in a new, confirmatory clinical study.
The letter also outlined that a serious event of electrocardiogram QT interval prolongation occurred, for which attribution to drug could not be excluded. Therefore a dedicated thorough QT study to evaluate the effect of macimorelin on the QT interval would be necessary.
The FDA complete response letter marks Aeterna Zentaris’ latest setback over the past nearly two years. In June, the company disclosed plans to slice its workforce to 65 staffers from the 90 it employed at the start of 2014—part of a “resources optimization program” that Dodd said was intended to “streamline our operations, optimize our resources and R&D productivity, reduce our operating cash burn and more appropriately, align our financial resources with our strategic goal of transitioning into a commercially operating specialty biopharmaceutical company.”
Last year, Aeterna Zentaris halted a Phase III trial that assessed perifosine in combination with bortezomib (Velcade®) and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma. The company cited the recommendation of the study’s independent data safety monitoring board, which concluded it was highly unlikely the study would achieve a significant difference in its primary endpoint, progression free survival. According to the company, no safety concerns were raised.
____________________________________
http://www.genengnews.com/gen-news-highlights/aeterna-zentaris-ponders-macrilen-s-future-after-fda-setback/81250566/
AEZS
Recent AEZS News
- Aeterna Zentaris Announces Effective Date of Share Consolidation • GlobeNewswire Inc. • 05/01/2024 11:55:00 AM
- Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris • GlobeNewswire Inc. • 03/28/2024 11:55:00 AM
- Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris • GlobeNewswire Inc. • 03/28/2024 11:55:00 AM
- Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency • GlobeNewswire Inc. • 03/27/2024 12:05:00 PM
- Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings • GlobeNewswire Inc. • 03/12/2024 06:10:53 PM
- Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings • GlobeNewswire Inc. • 03/12/2024 06:10:00 PM
- Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company • GlobeNewswire Inc. • 02/26/2024 12:30:00 PM
- Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company • GlobeNewswire Inc. • 02/26/2024 12:30:00 PM
- Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro • GlobeNewswire Inc. • 02/15/2024 10:50:00 PM
- Form F-1 - Registration statement for certain foreign private issuers • Edgar (US Regulatory) • 02/15/2024 09:54:45 PM
- Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend] • Edgar (US Regulatory) • 02/15/2024 02:33:18 PM
- Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] • Edgar (US Regulatory) • 12/22/2023 09:42:20 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/14/2023 12:50:09 PM
- Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company • GlobeNewswire Inc. • 12/14/2023 12:50:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/09/2023 01:05:28 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 11/09/2023 01:05:15 PM
- Aeterna Zentaris Reports Third Quarter 2023 Financial Results • GlobeNewswire Inc. • 11/09/2023 01:00:00 PM
- Aeterna Zentaris to Participate at the Virtual Investor Ask the CEO Conference • GlobeNewswire Inc. • 10/11/2023 12:00:00 PM
- Aeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Investment Conference • GlobeNewswire Inc. • 09/05/2023 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/09/2023 12:05:31 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 08/09/2023 12:05:18 PM
- Aeterna Zentaris Reports Second Quarter 2023 Financial Results • GlobeNewswire Inc. • 08/09/2023 12:05:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 07/13/2023 11:30:15 AM
- Aeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate Update • GlobeNewswire Inc. • 07/13/2023 11:30:00 AM
- Aeterna Zentaris to Participate in the Virtual Investor Summer Spotlight Series • GlobeNewswire Inc. • 07/05/2023 12:45:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM